Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Fesoterodine "add-on" Male Overactive Bladder Study

ClinicalTrials.gov ID: NCT00546637

Public ClinicalTrials.gov record NCT00546637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

Study identification

NCT ID
NCT00546637
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
947 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Jan 31, 2009
Completion
Jan 31, 2009
Last update posted
Feb 17, 2011

2007 – 2009

United States locations

U.S. sites
62
U.S. states
25
U.S. cities
56
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35209
Pfizer Investigational Site Gilbert Arizona 85234
Pfizer Investigational Site Gilbert Arizona 85295
Pfizer Investigational Site Litchfield Park Arizona 85340
Pfizer Investigational Site Mesa Arizona 85210
Pfizer Investigational Site Phoenix Arizona 85021
Pfizer Investigational Site Tucson Arizona 85712
Pfizer Investigational Site La Mesa California 91942
Pfizer Investigational Site Newport Beach California 92660
Pfizer Investigational Site San Bernardino California 92404
Pfizer Investigational Site San Diego California 92103-6204
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site Aurora Colorado 80012
Pfizer Investigational Site Denver Colorado 80211
Pfizer Investigational Site Jupiter Florida 33458
Pfizer Investigational Site Orange City Florida 32763
Pfizer Investigational Site West Palm Beach Florida 33401
Pfizer Investigational Site Dunwoody Georgia 30338
Pfizer Investigational Site Evansville Indiana 47713
Pfizer Investigational Site Jeffersonville Indiana 47130
Pfizer Investigational Site Newburgh Indiana 47630
Pfizer Investigational Site Des Moines Iowa 50309
Pfizer Investigational Site Iowa City Iowa 52242
Pfizer Investigational Site Baltimore Maryland 21204
Pfizer Investigational Site Owings Mills Maryland 21117
Pfizer Investigational Site Watertown Massachusetts 02472
Pfizer Investigational Site Flint Michigan 48507
Pfizer Investigational Site Saint Clair Shores Michigan 48081
Pfizer Investigational Site Troy Michigan 48084
Pfizer Investigational Site Utica Michigan 48081
Pfizer Investigational Site West Bloomfield Michigan 48322
Pfizer Investigational Site West Bloomfield Michigan 48323
Pfizer Investigational Site Minneapolis Minnesota 55455
Pfizer Investigational Site Omaha Nebraska 68114
Pfizer Investigational Site Sewell New Jersey 08080
Pfizer Investigational Site Albany New York 12208
Pfizer Investigational Site Garden City New York 11530
Pfizer Investigational Site Kingston New York 12401
Pfizer Investigational Site New York New York 10016
Pfizer Investigational Site Poughkeepsie New York 12601
Pfizer Investigational Site Syracuse New York 13210
Pfizer Investigational Site Williamsville New York 14221
Pfizer Investigational Site Durham North Carolina 27710
Pfizer Investigational Site Greensboro North Carolina 27403
Pfizer Investigational Site Fargo North Dakota 58103
Pfizer Investigational Site Fargo North Dakota 58104
Pfizer Investigational Site Cincinnati Ohio 45242
Pfizer Investigational Site Columbus Ohio 43214
Pfizer Investigational Site Columbus Ohio 43220
Pfizer Investigational Site Bethany Oklahoma 73008
Pfizer Investigational Site Portland Oregon 97239
Pfizer Investigational Site Bala-Cynwyd Pennsylvania 19004
Pfizer Investigational Site Camp Hill Pennsylvania 17011
Pfizer Investigational Site Pittsburgh Pennsylvania 15213
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Greer South Carolina 29650
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Austin Texas 78759
Pfizer Investigational Site Houston Texas 77024
Pfizer Investigational Site Tacoma Washington 98431-1100
Pfizer Investigational Site Madison Wisconsin 53715
Pfizer Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00546637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2011 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00546637 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →